Pull 4 Parkinson’s Foundation, Inc., a registered 501(c)(3) public charity,
funds cure and care research conducted by the Parkinson's disease community.
Learn More or Donate.

2555 Parkinson’s Trials Are Being Tracked

Trial Name Last Updated
T2000 in Essential Tremor - Open Label Continuation 10/07/2009
Study of the Effects of Dopaminergic Medications on Dopamine Transporter Density in Subjects With Parkinson's Disease 08/28/2009
Safety Study of Galantamine in Tic Disorders 08/25/2009
Magnetic Resonance Imaging (MRI) of Brain Iron in Neurodegenerative Disease 08/24/2009
Safety and Tolerability Study of Cogane™ in Healthy Volunteers and Parkinson's Disease Patients 08/21/2009
A Multi-Center Study of MYOBLOC for the Treatment of Sialorrhea in Parkinson's Disease Patients 08/13/2009
Automatic Detection of Falls and Near Falls 07/29/2009
Dose-Finding Safety Study of BIIB014 in Combination With Levodopa in Moderate to Late Stage Parkinson's Disease 07/13/2009
Twins and the Risk of Parkinson's Disease: A Clinical and Imaging Study 07/02/2009
Rajavtihi Neuronal Adult Stem Cells Project 06/24/2009
123I-ALTROPANE® Reference Image Acquisition in Subjects With Diagnostically Uncertain Tremor 05/29/2009
Treadmill Training and Quality of Life in Parkinson's Disease 05/04/2009
Trial of Xyrem for Excessive Daytime Sleepiness and Sleep Disturbance in Parkinson's Disease (PD) 05/01/2009
Namenda (Memantine) for Non-Motor Symptoms in Parkinson's Disease 05/01/2009
The Study of the Impact of Disclosing Imaging Study Information to Trial Participants 04/21/2009
Prospective Huntington At Risk Observational Study 04/16/2009
Pilot Randomized Controlled Trial of Telemedicine for Individuals With Parkinson Disease in a Rural Population 04/13/2009
The Effectiveness of Biofeedback Treatment in Constipated Patients With Idiopathic Parkinson's Disease 03/26/2009
Impact of Switching to Continuous Release Dopamine Agonists 03/19/2009
Parcopa Versus Carbidopa-Levodopa in a Single Dose Cross-Over Comparison Study 03/16/2009
Tolerability and Efficacy of Switch From Oral Selegiline to Orally Disintegrating Selegiline (Zelapar) in Patients With Parkinson's Disease 03/16/2009
Botulinum Toxin Type A (Botox) in the Management of Levodopa-Induced Peak-Dose Dyskinesias in Parkinson's Disease 02/16/2009

Page 113 of 117 pages ‹ First  < 111 112 113 114 115 >  Last ›

All ClinicalTrials.gov articles provided courtesy of National Library of Medicine (NLM).